Saturday 17 October 2026
Export PMN’s income statement to Excel — free account
Promis Neurosciences
In the quarter to June 2026, EPS grew 82.3% and free cash flow fell 169.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.15
0.55
−6.32%
Follow PMN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
7.41 | 9.65 | 0.59 | 1.26 | |
Current Ratio |
7.85 | 9.92 | 0.88 | 1.76 | |
Net Debt/EBITDA |
4.36 | 7.39 | 0.57 | 1.31 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.89 | 1.50 | 0.87 | 0.87 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.14) | (1.90) | (5.28) | (5.15) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.14) | (1.90) | (5.28) | (5.15) | |
Cash per Share |
5.85 | 9.78 | 3.50 | 7.90 | |
Shareholders Equity per Share |
5.40 | 9.30 | (0.72) | 4.70 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.40 | 9.30 | (0.72) | 4.70 | |
Free Cash Flow |
(10.39) | (12.38) | (9.28) | (10.06) | |
Working Capital |
49.48 | 59.00 | (1.23) | 9.25 | |
Net Current Asset Value |
49.40 | 58.92 | (1.26) | 9.19 | |
| Other line items | |||||
Average Payables |
2.29 | 1.46 | 2.14 | 2.89 | |
Average Assets |
33.10 | 40.53 | 14.05 | 22.98 | |
Average Common Equity |
24.51 | 35.09 | 7.61 | 8.23 |
Columns are period end dates